第二款胆管癌靶向药物—英菲格拉替尼获批上市

Infigratinib is an ATP-competitive, oral tyrosine kinase FGFR1~3 inhibitor. On May 29, 2021, the US FDA approved it for the treatment of cholangiocarcinoma, targeting cholangiocarcinoma with FGFR2 fusion gene mutations.

A multi-center, single-group clinical study enrolled a total of 71 subjects to evaluate the efficacy of Infigratinib as a third-line or above treatment for patients with FGFR2 fusion-positive cholangiocarcinoma. The results showed that in the case of second-line treatment, the median progression-free survival (PFS) of patients was 4.63 months; the median progression-free survival (PFS) of patients who received third-line and above treatment with Infigratinib was 6.77 months; the objective response rate (ORR) of patients who received third-line and above treatment was 21.6%.

In a phase II clinical trial, 108 patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement mutations were treated with Infigratinib after their disease progressed on gemcitabine chemotherapy. The objective response rate (ORR) of the treatment reached 23.1%. The lesion disappeared completely in one patient, and more than 30% reduction of the lesion was seen in 24 patients. The disease control rate is as high as 84.3%. The median progression-free survival (PFS) for all patients was 7.3 months.

Infigratinib can prolong the progression-free survival of patients, improve the remission rate and disease control rate, improve the patient's quality of life and disease progression, and can have a positive effect on the patient's condition.

The above is an introduction to Infigratinib. If patients want to know more about the latest drug information about this drug (such as the price of Infigratinib, purchase methods, precautions, etc.), they can contact the Medical Companion Travel Service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: